UCB announced today that Norman J Ornstein is to be appointed as a new member of the Board of Directors at the next General Assembly.
Norman Ornstein is resident Scholar at the American Enterprise Institute, Washington, DC, and an expert in US congress matters. He is PhD Political Science, University of Michigan and Honorary Doctor of Laws, University of Minnesota.
By the next General Assembly on 24 April 2008, mandates of four Directors will come to an end. With a view to further broadening the skills of the Board, four candidates as independent Board members have already been selected, including those announced in December 2007: Thomas Leysen, CEO of Umicore and next Chairman of the FEB (Federation of Belgian Companies), who will join the Board of UCB as of 1 January 2009; Jean-Pierre Kinet, Professor at Harvard Institute of Medicine and at the Beth Israel Deaconess Medical Center in the US; Armand De Decker, President of the Belgian Senate; and Norman Ornstein.
Brussels-based UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007.